Pharmacological compounds with BRAF kinase blocking activity were shown to inhibit the secretion of CXCL8 in melanoma cell lines harboring the BRAFV600E mutation2, but their effect in thyroid cancer cells remains to be investigated. The gene discussed is BRAF; the disease is melanoma.